c-Abl-regulated MT dynamics may also provide alternative approaches for the development of therapeutics, since c-Abl inhibitors such as STI571, nilotinib, and bafetinib have been successfully used in the treatment of blood and solid tumors and have shown efficacy in animal models of PD. The gene discussed is ABL1; the disease is Parkinson disease.